Irish Continental Group (ICGC) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
19 Aug, 2026Executive summary
Revenue rose 16.1% year-over-year to €359.9m, driven by higher freight volumes and cost recovery, despite a challenging macro environment and increased operating costs.
EBITDA increased 7.3% to €58.9m, but operating profit declined 2.4% to €24.0m due to higher fuel, port, and environmental costs.
Net profit was €18.6m, with basic EPS up 5.9% to 12.5c.
A recommended €8.00/share cash offer from Bluefin Bidco Limited values the company at €1.2bn; transaction expected to close in Q4 2026, pending approvals.
Financial highlights
Revenue: €359.9m (+16.1% YoY); EBITDA: €58.9m (+7.3% YoY); Operating profit: €24.0m (-2.4% YoY); Net profit: €18.6m.
Net debt: €226.2m (down from €256.1m at year-end); Net debt pre-IFRS 16: €176.5m (+45.7% YoY).
Basic EPS: 12.5c (+5.9% YoY); Adjusted basic EPS: 11.6c.
Final dividend of 10.95c/share paid for FY25; no interim dividend proposed for 2026 due to pending acquisition.
Outlook and guidance
Second half typically generates two-thirds of annual EBITDA, but volume weakness in car and freight markets during peak summer is a significant concern.
High fuel prices and weak car market challenge the ability to pass on cost increases.
Directors expect adequate resources for at least 12 months and continue to adopt the going concern basis.
Latest events from Irish Continental Group
- Revenue up 13.9% as freight growth and surcharges offset softer car and container volumes.ICGC
Trading update - Revenue and profit growth continued, but net debt rose amid major investments and buybacks.ICGC
H2 2025 - Revenue up 10% to €573m, with higher freight volumes and increased net debt from vessel buys.ICGC
Trading Update - Revenue up 8.5% and EBITDA up 10.5% in H1 2025, driven by strong container growth.ICGC
H1 2025 - Revenue and volumes up, but net debt and regulatory risks also increased.ICGC
H1 2024 - Revenue and EBITDA grew, but regulatory costs and market rates remain key risks.ICGC
H2 2024